Dataset Information


Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial.

ABSTRACT: PURPOSE:The treatment outcome of brentuximab vedotin (BV) has not been related with CD30 expression in previous studies enrolling patients with a wide range of CD30 expression level. Thus, this study explored the efficacy of BV in high-CD30-expressing non-Hodgkin lymphoma (NHL) patients most likely to benefit. MATERIALS AND METHODS:This phase II study (Clinicaltrials.gov: NCT02280785) enrolled relapsed or refractory high-CD30-expressing NHL, with BV administered intravenously at 1.8 mg/kg every 3 weeks. The primary endpoint was > 40% disease control rate, consisting of complete response (CR), partial response (PR), or stable disease. We defined high CD30 expression as ? 30% tumor cells positive for CD30 by immunohistochemistry. RESULTS:High-CD30-expressing NHL patients (n=33) were enrolled except anaplastic large cell lymphoma. The disease control rate was 48.5% (16/33) including six CR and six PR; six patients (4CR, 2PR) maintained their response over 16 completed cycles. Response to BV and survival were not associated with CD30 expression levels. Over a median of 29.2 months of follow-up, the median progression-free and overall survival rates were 1.9 months and 6.1 months, respectively. The most common adverse events were fever (39%), neutropenia (30%), fatigue (24%), and peripheral sensory neuropathy (27%). In a post-hoc analysis for the association of multiple myeloma oncogene 1 (MUM1) on treatment outcome, MUM1- negative patients showed a higher response (55.6%, 5/9) than MUM1-positive patients (13.3%, 2/15). CONCLUSION:BV performance as a single agent was acceptable in terms of disease control rates and toxicity profiles, especially MUM1-negative patients.

PROVIDER: S-EPMC7176958 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC8799538 | BioStudies
| S-EPMC5078781 | BioStudies
| S-EPMC5218629 | BioStudies
2019-01-01 | S-EPMC6647393 | BioStudies
| S-EPMC6516120 | BioStudies
| S-EPMC4171358 | BioStudies
| S-EPMC5669573 | BioStudies
| S-EPMC6693006 | BioStudies
| S-EPMC4031906 | BioStudies
| S-EPMC5035790 | BioStudies